Neuropace, Inc. NPCE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $99.53M+18.1% | $99.99M+25.1% | $94.86M+24.1% | $88.57M+23.3% | $84.31M+22.1% | ||
| $21.6M+1.8% | $22.77M+9.3% | $22.03M+10.1% | $21.49M+15.8% | $21.22M+18.0% | ||
| $77.93M+23.5% | $77.22M+30.7% | $72.83M+29.0% | $67.08M+26.0% | $63.08M+23.5% | ||
| 78.3%+3.5pp | 77.2%+3.3pp | 76.8%+2.9pp | 75.7%+1.6pp | 74.8%+0.9pp | ||
| $27.64M+9.2% | $27.89M+17.9% | $26.91M+17.1% | $26.09M+18.5% | $25.31M+18.8% | ||
| $47.16M+16.0% | $46.58M+17.4% | $45.6M— | $42.93M— | $40.64M— | ||
| $19.89M+21.2% | $19.09M+9.5% | $18.55M— | $17.93M— | $16.41M— | ||
| $94.69M+15.0% | $93.56M+15.9% | $91.05M+14.5% | $86.95M+11.4% | $82.36M+6.3% | ||
| $94.69M+15.0% | $93.56M+15.9% | $91.05M+14.5% | $86.95M+11.4% | $82.36M+6.3% | ||
| -$16.76M+13.0% | -$16.34M+24.6% | -$18.22M+21.0% | -$19.87M+19.8% | -$19.27M+27.0% | ||
| -16.8%+6.0pp | -16.3%+10.8pp | -19.2%+11.0pp | -22.4%+12.1pp | -22.9%+15.4pp | ||
| $6.83M-21.5% | $7.46M-15.2% | $8.05M-9.0% | $8.59M-3.0% | $8.69M-1.3% | ||
| $2.59M-13.4% | $2.82M-6.9% | $2.86M-9.7% | $2.95M-7.4% | $2.99M-5.1% | ||
| -$569K— | -$486K— | —— | —— | —— | ||
| -$21.57M+13.1% | -$21.47M+20.9% | -$23.99M+14.6% | -$25.94M+13.2% | -$24.81M+21.3% | ||
| -21.7%+7.8pp | -21.5%+12.5pp | -25.3%+11.5pp | -29.3%+12.3pp | -29.4%+16.2pp | ||
| -$0.65+21.7% | -$0.66+29.8% | -$0.75+24.2% | -$0.83+23.1% | -$0.83+29.7% | ||
| -$0.65+21.7% | -$0.66+29.8% | -$0.75+24.2% | -$0.83+23.1% | -$0.83+29.7% | ||
| 132.4M+11.4% | 130.2M+12.5% | 126.6M+12.6% | 122.9M+12.8% | 118.9M+12.6% | ||
| 132.4M+11.4% | 130.2M+12.5% | 126.6M+12.6% | 122.9M+12.8% | 118.9M+12.6% | ||
| -$569K— | -$486K— | —— | —— | —— | ||
| $99.53M+18.1% | $99.99M+25.1% | $94.86M+24.1% | $88.57M+23.3% | $84.31M+22.1% | ||
| -$16.76M+13.0% | -$16.34M+24.6% | -$18.22M+21.0% | -$19.87M+19.8% | -$19.27M+27.0% | ||
| -$16.42M+13.5% | -$16.01M+25.1% | -$17.93M+21.3% | -$19.57M+20.1% | -$18.98M+27.3% | ||
| -$16.42M+13.5% | -$16.01M+25.1% | -$17.93M+21.3% | -$19.57M+20.1% | -$18.98M+27.3% | ||
| -16.5%+6.0pp | -16%+10.7pp | -18.9%+10.9pp | -22.1%+12.0pp | -22.5%+15.3pp | ||
| -$16.76M+13.0% | -$16.34M+24.6% | -$18.22M+21.0% | -$19.87M+19.8% | -$19.27M+27.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neuropace, Inc.'s revenue?
- Neuropace, Inc. (NPCE) generated $99.5M in revenue over the trailing twelve months, up 18.1% year over year.
- Is Neuropace, Inc. profitable?
- Neuropace, Inc. is not currently profitable: it reported a net loss of $21.6M over the trailing twelve months, a -21.7% net margin.
- What are Neuropace, Inc.'s profit margins?
- Gross margin is 78.3% and operating margin is -16.8%, with a -21.7% net margin.
- What is Neuropace, Inc.'s earnings per share?
- Neuropace, Inc.'s diluted EPS over the trailing twelve months is $-0.65.
- Where does Neuropace, Inc.'s income statement data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
